BSE:524396

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Biofil Chemicals and Pharmaceuticals

Executive Summary

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Biofil Chemicals and Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 524396's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

21.4%

524396

-1.9%

IN Pharmaceuticals

-0.5%

IN Market


1 Year Return

1,950.0%

524396

50.1%

IN Pharmaceuticals

2.0%

IN Market

Return vs Industry: 524396 exceeded the Indian Pharmaceuticals industry which returned 50.1% over the past year.

Return vs Market: 524396 exceeded the Indian Market which returned 2% over the past year.


Shareholder returns

524396IndustryMarket
7 Day21.4%-1.9%-0.5%
30 Day45.1%-4.3%0.3%
90 Day315.8%13.6%7.1%
1 Year1,950.0%1,950.0%52.0%50.1%3.7%2.0%
3 Year251.9%251.9%27.5%24.0%2.0%-3.0%
5 Year889.1%889.1%-0.5%-4.0%40.9%30.4%

Price Volatility Vs. Market

How volatile is Biofil Chemicals and Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biofil Chemicals and Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

98.65x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 524396 (₹82) is trading above our estimate of fair value (₹0.52)

Significantly Below Fair Value: 524396 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 524396 is poor value based on its PE Ratio (98.7x) compared to the IN Pharmaceuticals industry average (23x).

PE vs Market: 524396 is poor value based on its PE Ratio (98.7x) compared to the Indian market (16.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 524396's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 524396 is overvalued based on its PB Ratio (7.4x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Biofil Chemicals and Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biofil Chemicals and Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biofil Chemicals and Pharmaceuticals performed over the past 5 years?

3.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 524396 has high quality earnings.

Growing Profit Margin: 524396's current net profit margins (4.6%) are higher than last year (2.6%).


Past Earnings Growth Analysis

Earnings Trend: 524396's earnings have grown by 3% per year over the past 5 years.

Accelerating Growth: 524396's earnings growth over the past year (160.5%) exceeds its 5-year average (3% per year).

Earnings vs Industry: 524396 earnings growth over the past year (160.5%) exceeded the Pharmaceuticals industry 14.7%.


Return on Equity

High ROE: 524396's Return on Equity (9.3%) is considered low.


Next Steps

Financial Health

How is Biofil Chemicals and Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 524396's short term assets (₹322.7M) exceed its short term liabilities (₹274.8M).

Long Term Liabilities: 524396 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 524396's debt to equity ratio (8%) is considered satisfactory.

Reducing Debt: 524396's debt to equity ratio has reduced from 35.4% to 8% over the past 5 years.

Debt Coverage: 524396's debt is well covered by operating cash flow (87.5%).

Interest Coverage: 524396's interest payments on its debt are well covered by EBIT (41.6x coverage).


Balance Sheet


Next Steps

Dividend

What is Biofil Chemicals and Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524396's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524396's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524396's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524396's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 524396's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average board tenure


CEO

Ramesh Shah (84 yo)

no data

Tenure

Mr. Ramesh S. Shah serves as the Managing Director of Biofil Chemicals & Pharmaceuticals Ltd. and served as its Compliance Officer. Mr. Shah serves as the Chairman of Biofil Chemicals & Pharmaceuticals Ltd ...


Board Members

NamePositionTenureCompensationOwnership
Ramesh Shah
Chairmanno datano data4.88%
₹ 65.1m
Ketan Shah
COO & Whole Time Director0.17yr₹1.74m2.09%
₹ 27.9m
Romil Shah
Non-Executive Director15.25yrsno data2.35%
₹ 31.4m
Shaila Jain
Independent Director17.75yrsno datano data
Subhash Swarnkar
Independent Director5.17yrsno datano data
Ashok Ramawat
Independent Director0.17yrno datano data

5.2yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 524396's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biofil Chemicals and Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biofil Chemicals and Pharmaceuticals Limited
  • Ticker: 524396
  • Exchange: BSE
  • Founded: 1985
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.334b
  • Shares outstanding: 16.27m
  • Website: https://www.biofilgroup.net

Number of Employees


Location

  • Biofil Chemicals and Pharmaceuticals Limited
  • B-12/B, Industrial Estate
  • Pologround
  • Indore
  • Madhya Pradesh
  • 452015
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
524396BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2001
BIOFILCHEMNSEI (National Stock Exchange of India)YesEquity SharesININRDec 2001

Biography

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chlor ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 12:48
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.